menu
Investors & Media

Press Releases

Press Releases

Keyword Search

Nov 24, 2021
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
Nov 18, 2021
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Nov 12, 2021
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Nov 09, 2021
Ionis to present at upcoming virtual investor conferences
Nov 07, 2021
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
Nov 03, 2021
Ionis reports third quarter 2021 financial results and recent business achievements
Nov 02, 2021
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Oct 20, 2021
Ionis to hold third quarter 2021 financial results webcast
Oct 17, 2021
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 14, 2021
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Sep 03, 2021
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
Sep 02, 2021
Ionis to present at upcoming virtual investor conferences
Aug 04, 2021
Ionis reports second quarter 2021 financial results and recent business achievements
Aug 02, 2021
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Jul 29, 2021
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Jul 26, 2021
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Jul 21, 2021
Ionis to hold second quarter 2021 financial results webcast
Jul 13, 2021
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
Jun 14, 2021
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
Jun 10, 2021
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
Jun 02, 2021
Ionis announces changes to its board of directors at annual meeting of stockholders
May 26, 2021
Ionis to present at upcoming investor conferences
May 06, 2021
Ionis to present at upcoming investor conferences
May 05, 2021
Ionis to host 2021 virtual annual meeting of stockholders
May 05, 2021
Ionis reports first quarter 2021 financial results and recent business achievements
Apr 21, 2021
Ionis to hold first quarter 2021 financial results webcast
Apr 20, 2021
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
Apr 08, 2021
Ionis prices private placement of convertible senior notes
Apr 06, 2021
Ionis announces proposed private placement of convertible notes
Apr 05, 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Mar 29, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Mar 26, 2021
Ionis to present at upcoming investor conferences
Mar 22, 2021
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
Mar 01, 2021
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
Feb 24, 2021
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
Feb 19, 2021
Ionis to present at upcoming investor conferences
Feb 11, 2021
Ionis to hold 2020 financial results webcast
Jan 07, 2021
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Jan 05, 2021
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
Load More »